Self-administration of subcutaneous depot medroxyprogesterone acetate (DMPA) can improve contraceptive access and continuation and is a practicable option for women and adolescents, a recent study found. 401 females aged 16 to 44 years and requesting DMPA at clinics in Texas and New Jersey were randomized 1:1 to self-administration or clinic administration. Those randomized to self-administration were taught to self-inject and received instructions, a sharps container, and 3 doses for home use. Follow-up surveys were conducted at 6 and 12 months. Researchers found:
- 336 (84%) participants completed with 12-month survey; 316 (80%) completed both follow-up surveys.
- 1-year DMPA continuous use was 69% in the self-administration group vs 54% in the clinic group.
- 97% of women in the self-administration group reported that self-administration was very or somewhat easy and 87% would recommend it to a friend.
- 52% of women in the clinic group reported interest in self-administration in the future.
- No serious adverse events were reported.
Kohn JE, Simons HR, Badia LD, et al. Increased one-year continuation of DMPA among women randomized to self-administration: Results from a randomized controlled trial at Planned Parenthood. [Published online ahead of print December 12, 2017]. Contraception. doi:10.1016/j.contraception.2017.11.009.
This Week's Must Reads
Must Reads in Contraception
Bleeding and Spotting with the LNG 13.5 mg IUS, Contraception; ePub 2019 Mar 1; Shimoni, et al
Contraception and Chronic Opioid Prescriptions, Contraception; ePub 2019 Feb 11; Ray-Griffith, et al
Hormonal Contraception & Coexisting Medical Conditions, Obstet Gynecol; ePub 2019 Feb; Allen, et al
Contraceptive Switching & Discontinuation, Am J Obstet Gynecol; ePub 2018 Dec 18; Simmons, et al
Efficacy of a Levonorgestrel 52-mg IU System, Obstet Gynecol; ePub 2018 Dec 4; Teal, et al